Mental Health Inequalities

Risks & contraindications

Comparisons

Evidence quality

Highlighted claims

• Young people from marginalised groups experience higher mental health symptoms and greater barriers to support. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
• LGBTQIA+ young women and men face elevated risks of depression, anxiety, and suicide. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
• Minoritised ethnic young people are more likely than white British peers to receive mental healthcare through compulsory routes. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
• Neurodivergent needs in young women are often unrecognised or mislabelled, delaying support. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial
• Only about a quarter of young people with mental health difficulties receive specialist support. — Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial